AC Immune S.A. (NQ: ACIU )
3.370
-0.020
(-0.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
All News about AC Immune S.A.
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/06/14/xrdDAFekDI-j282-j1745615867-t23032908.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/05/31/Movers.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/05/31/xrdDAFkez9BskM2-j7952622998620176998-t23.jpeg?width=1200&height=800&fit=crop)
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/05/23/xrdDAFj7f9vwuY2-j5446957451-t23052513.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/05/15/xrdDAFfORZ4lNo2-j2185570849-t23040509.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://cdn.benzinga.com/files/images/story/2024/05/13/Businessman-Tablet-Stocks-Shutterstock.jpeg?width=1200&height=800&fit=crop)
Gold Down Over 1%; AC Immune Shares Spike Higher
May 13, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/05/13/Brain-Degenerative-Diseases-Parkinson--A.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/05/13/movers.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/05/13/Wall-Street-US-Stocks.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
Exposures
Fossil Fuels
![](https://investorplace.com/wp-content/uploads/2023/09/rnaz1600.png)
![](https://investorplace.com/wp-content/uploads/2023/11/sgd1600-1024x576.png)
![](https://investorplace.com/wp-content/uploads/2020/07/medicine-1.jpg)
![](https://investorplace.com/wp-content/uploads/2021/10/wall-street-bull.jpg)
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
![](https://mms.businesswire.com/media/20240510475155/en/2127419/22/ACI_Logo.jpg)
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
February 22, 2024
From AC Immune SA
Via GlobeNewswire
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
January 22, 2024
From AC Immune SA
Via GlobeNewswire
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/12/15/aciu.png?optimize=medium&dpr=1&auto=webp&height=630&width=1200&fit=crop)
![](https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg)
AC Immune Announces Pricing of Underwritten Offering of Common Shares
December 15, 2023
From AC Immune SA
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.